Cargando…
Abiraterone-induced refractory hypokalaemia and torsades de pointes in a patient with metastatic castration-resistant prostate carcinoma: a case report
BACKGROUND: Abiraterone, an androgen deprivation therapy, has been used in the treatment of metastatic castration-resistant prostate cancer (mCRPC). It has been associated with increased risks of hypokalaemia and cardiac disorders. We report a case of torsades de pointes (TdP) associated with abirat...
Autores principales: | Riad, Mariam, Allison, Jeffery Scott, Nayyal, Shahla, Hritani, AbdulWahab |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8849113/ https://www.ncbi.nlm.nih.gov/pubmed/35187388 http://dx.doi.org/10.1093/ehjcr/ytab462 |
Ejemplares similares
-
Abiraterone/potassium-chloride: Hypokalaemia, torsades de pointes and lack of efficacy: case report
Publicado: (2022) -
Abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Mostaghel, Elahe A
Publicado: (2014) -
A Case of Abiraterone-Related Hypokalemia Leading to Torsades de Pointes and Cardiac Arrest
por: Lee, Dae Hyun, et al.
Publicado: (2022) -
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
por: Chi, Kim N., et al.
Publicado: (2023) -
Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Zobniw, Chrystia M, et al.
Publicado: (2014)